166 related articles for article (PubMed ID: 27943100)
21. Association of
Fu W; Zhuo Z; Hua RX; Fu K; Jia W; Zhu J; Zhang J; Cheng J; Zhou H; Xia H; He J; Liu G
Aging (Albany NY); 2019 Mar; 11(5):1551-1563. PubMed ID: 30860980
[TBL] [Abstract][Full Text] [Related]
22. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
24. Adult Wilms Tumor: Genetic Evidence of Origin of a Subset of Cases From Metanephric Adenoma.
Argani P; Tickoo SK; Matoso A; Pratilas CA; Mehra R; Tretiakova M; Sibony M; Meeker AK; Lin MT; Reuter VE; Epstein JI; Gagan J; Palsgrove DN
Am J Surg Pathol; 2022 Jul; 46(7):988-999. PubMed ID: 35184066
[TBL] [Abstract][Full Text] [Related]
25. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
26. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
27. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
[TBL] [Abstract][Full Text] [Related]
28. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
30. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
[TBL] [Abstract][Full Text] [Related]
31. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
Abdelraouf F; Sharp A; Maurya M; Mair D; Wotherspoon A; Leary A; Gonzalez de Castro D; Bhosle J; Nassef A; Gaafar T; Popat S; Yap TA; O'Brien M
BMC Res Notes; 2015 Nov; 8():688. PubMed ID: 26581482
[TBL] [Abstract][Full Text] [Related]
32. Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.
Jesinghaus M; Pfarr N; Endris V; Kloor M; Volckmar AL; Brandt R; Herpel E; Muckenhuber A; Lasitschka F; Schirmacher P; Penzel R; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Jun; 55(6):505-21. PubMed ID: 26917275
[TBL] [Abstract][Full Text] [Related]
33. Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors.
Rignall B; Ittrich C; Krause E; Appel KE; Buchmann A; Schwarz M
J Proteome Res; 2009 Aug; 8(8):3987-94. PubMed ID: 19476384
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
35. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
37. Impact of different methodologies on the detection of point mutations in routine air-dried fine needle aspiration (FNA) smears.
Rehfeld C; Münz S; Krogdahl A; Jensen EM; Siebolts U; Ferraz C; Bösenberg E; Hegedüs L; Paschke R; Eszlinger M
Horm Metab Res; 2013 Jul; 45(7):513-7. PubMed ID: 23508716
[TBL] [Abstract][Full Text] [Related]
38. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
40. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
